What are the key differences in new drug product approvals across the US and EU regions? Learn about the state of drug approvals in the world's two largest markets.
On the 28th - 30th May, NDA will contribute to a 3 day Course in the Development of Biological Drugs in Stockholm and/or distance.
Don’t miss the opportunity to meet our Experts who will present on a number of critical drug development topics and be on hand to answer your questions.
Shelley Gandhi to conduct an Advanced Workshop in QPPV Toolbox – Your Key to Success – in conjunction with DIA Learning on the 12-13 March in Berlin.
Dr. Lönngren will present and discuss the common failures in drug development from a regulatory and market access perspective and how to avoid these failures.
Dr. Lönngren will address hot topics such as Brexit, expedited pathways, use of RWE in decision making, cost effectiveness and affordability.
NDAs Dr Paula Salmikangas will be moderating a 1-hour ‘Working Lunch’ Panel Discussion on “Safety aspects of genetically modified cells”.
Join us on 8th February to learn how to maximise safety and efficacy of novel cell-based cancer treatments.
The conference will bring together industry experts to explore the strategies to gain insight into new biosimilar development strategies.
Dr. Thomas Lönngren, Strategic Advisor NDA Group, has been invited to speak in the session 'Regulatory Hurdles: Access Across Borders' at the Europe CEO conference.
Join us on 30th November to get insight into the HOW to avoid market delays that impact patients and ultimately reimbursement.
If you are planning to attend this year’s PEGS Europe in Lisbon, we would really like to meet up with you.
NDAs Dr Lönngren has been invited to present on Regulatory development and alignment between the USA and Europe at the EMAP event 24th-26th October London.
Subscribe to the latest intelligence from the true thought leaders in the field and access it at any time.